证券日报网讯 12月16日晚间，方盛制药发布公告称，近日，公司收到湖南省药品监督管理局签发的 《药品 GMP 符合性检查告知书》。 （文章来源：证券日报） ...

Group 1 - Action Education plans to repurchase shares worth between 20 million to 25 million yuan at a price not exceeding 45 yuan per share for employee stock ownership plans or equity incentives [1] - Fulin Technology's shareholders plan to reduce their holdings by up to 2% of the company's total shares, amounting to a maximum of 24.44 million shares starting from December 22, 2025 [2] - Huashu shares' shareholders intend to reduce their holdings by up to 1% of the company's total shares, which is a maximum of 35.94 million shares [3] Group 2 - Silan Microelectronics has obtained a filing certificate for its 12-inch high-end analog integrated circuit chip manufacturing production line project, with an investment of 10 billion yuan and a monthly production capacity of 20,000 wafers [4] - Aerospace Information confirms that its main business does not involve commercial aerospace and that its operations are normal without significant changes [5] - Qinglong Pipe Industry signed a supply contract worth 294 million yuan for PCCP and pressure steel pipes, accounting for 10.43% of its 2024 revenue [6] Group 3 - Huaxin Precision plans to invest up to 1 billion yuan of idle funds in low-risk financial products [7] - Hainan Rubber received insurance compensation totaling approximately 26.65 million yuan for rubber income and tree insurance [8] - Lianmei Holdings announced the suspension of its subsidiary Fulin Thermal Power due to economic slowdown and reduced customer demand [9] Group 4 - Ruifeng Bank has been approved to issue up to 2.5 billion yuan in secondary capital bonds to enhance its capital and risk resistance [11] - China Pacific Insurance reported a 9.4% year-on-year increase in premium income for its life insurance subsidiary, totaling 250.32 billion yuan [12] - Sunshine Nuohuo signed an agreement with Peking University to establish a joint laboratory for innovative drug development [13] Group 5 - Century Huatong completed the cancellation of 56.12 million repurchased shares, reducing its total share capital from 7.428 billion to 7.372 billion shares [14] - Yaxin Security received a government subsidy of 3 million yuan [15] - Haili Biology's subsidiary received registration certification for a bone repair material in Indonesia [16] Group 6 - Yian Technology's subsidiary secured a major project for magnesium alloy components worth 430 million yuan, expected to start production by the end of March 2026 [17] - Jiangte Electric plans to contest the proposed cancellation of its lithium-containing mining rights [18] - COFCO Technology announced the resignation of its deputy general manager due to work changes [19] Group 7 - Fangsheng Pharmaceutical passed the GMP compliance inspection for its raw material production lines [21] - Bohai Ferry announced the resignation of two deputy general managers for personal and age-related reasons [22] - ST Fuhua appointed a new general manager [23] Group 8 - Huazhong CNC received project funding of 17.7 million yuan, accounting for 31.97% of its audited net profit for 2024 [24] - Oppein Home used 15 million yuan of idle funds to purchase a large time deposit with a 0.9% annual yield [25] - China General Nuclear Power's Ningde Unit 6 has begun full construction, utilizing Hualong One technology with a capacity of 1210 MW [26] Group 9 - Jiayuan Technology's chairman has had the investigation order lifted, and the company is operating normally [27] - Fulaixin Materials' application for a specific stock issuance has been approved by the Shanghai Stock Exchange [28] - Shuhua Sports plans to invest up to 500 million yuan in a health industry park project [29] Group 10 - Rhine Biology's stock will continue to be suspended due to ongoing control change and asset acquisition plans [30] - Haishi Science received approval for clinical trials for four innovative drugs targeting various diseases [31] - Hangcai Co. plans to repurchase shares worth between 50 million to 100 million yuan at a price not exceeding 80 yuan per share [32] Group 11 - Yinxin Technology received a cash dividend of 18 million yuan from its subsidiary [33] - Tianfulong plans to increase its wholly-owned subsidiary's capital by 580 million yuan [34] - Poly United's subsidiary won a bid for a stripping project worth 1.528 billion yuan [35] Group 12 - Minglida's deputy general manager resigned due to health reasons [36] - ST Guohua appointed a new deputy general manager [37] - China Xidian's subsidiaries won contracts totaling 1.005 billion yuan for Southern Power Grid projects [38]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-104 湖南方盛制药股份有限公司 关于公司通过药品GMP符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，湖南方盛制药股份有限公司（以下简称"公司"）收 到湖南省药品监督管理局签发的《药品 GMP 符合性检查告知书》， 现就相关情况公告如下： 三、对公司的影响及风险提示 第 1 页，共 2 页 公司本次获得药品 GMP 符合性检查结果，表明公司相关生 产线符合 GMP 要求，有利于公司进一步丰富生产品种，保持稳 二、本次检查所涉生产线情况 生产线名称 设计产能 主要生产品种 原料药车间（101 车间）B 区与 E 区依 折麦布生产线 依折麦布原料药 4,000kg/年 依折麦布 原料药车间（101 车间）A 区与 E 区盐 酸贝尼地平生产线 盐酸贝尼地平原料药 500kg/年 盐酸贝尼地平 湖南方盛制药股份有限公司 HUNANFANGSH ...

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received a GMP compliance inspection notice from the Hunan Provincial Drug Administration, indicating that its production lines meet GMP requirements, which will help the company diversify its product offerings and maintain stable production capacity to meet market demand [1] Group 1 - The company received the GMP compliance inspection notice for its production facilities located in the Hunan Wangcheng Economic Development Zone [1] - The inspection covered the production lines for Ezetimibe and Benidipine in the raw material drug workshop [1] - The compliance with GMP standards is expected to enhance the company's ability to meet market needs and ensure stable production capabilities [1]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received a GMP compliance inspection notice from the Hunan Provincial Drug Administration, indicating regulatory approval for specific production lines [1] Group 1: Company Announcement - The company announced the receipt of the GMP compliance inspection notice [1] - The inspection covers the production lines for Ezetimibe and Benidipine in the raw material drug workshop [1] - Specific areas inspected include the B and E zones for Ezetimibe and the A and E zones for Benidipine [1]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received a GMP compliance inspection notice from the Hunan Provincial Drug Administration, indicating progress in regulatory compliance for its production facilities [1] Group 1: Inspection Details - The inspection covers the production lines for Ezetimibe and Benidipine in the raw material drug workshop [1] - Specific areas inspected include Zone B and Zone E for Ezetimibe, and Zone A and Zone E for Benidipine in the raw material drug workshop [1]

Core Viewpoint - The company, Fangsheng Pharmaceutical, has successfully passed the GMP compliance inspection conducted by the Hunan Provincial Drug Administration, which is expected to enhance its production capacity and product variety to meet market demand [1] Group 1: Inspection Details - The GMP compliance inspection took place on July 8, 2025, and from July 15 to 17, 2025 [1] - The inspection covered the raw material drug workshops, specifically the production lines for Ezetimibe and Benidipine [1] - The designed production capacity for Ezetimibe raw materials is 4000 kg per year, while for Benidipine raw materials, it is 500 kg per year [1] Group 2: Compliance and Impact - The inspection results met the requirements of the Drug Administration Law, the Drug Production Supervision and Administration Measures, and the Good Manufacturing Practice (GMP) for drug production [1] - The positive inspection outcome is beneficial for the company to diversify its product offerings and maintain stable production capabilities [1] - This development is crucial for the company to satisfy market demand effectively [1]

南方财经12月16日电，方盛制药(603998.SH)发布公告称，调整转让佰骏医疗部分股权方案。原定转让 5.1%股权（稀释后4.0157%，对应801万元）中，仅2.4409%用于分配（对应486.6466万元），剩余 1.5748%由子公司方盛康元通过瑞健健康持有。瑞健健康将减资并变更合伙人，方盛康元出资占比 20%。部分股权持有人（对应0.8152%股权）转让收益不足时，偿还上限为净收益，涉及金额最高170万 元，存在无法全额收回风险。 ...

（文章来源：证券日报） 证券日报网讯 12月15日晚间，方盛制药发布公告称，公司第六届董事会2025年第六次临时会议审议通 过《关于对子公司股权转让相关事项进行调整的议案》《关于拟注销部分子公司的议案》《关于使用闲 置自有资金进行现金管理的议案》等多项议案。 ...

湖南方盛制药股份有限公司 证券代码：603998 证券简称：方盛制药 公告编号：2025-099 湖南方盛制药股份有限公司 关于转让控股子公司部分股权暨引进战略投资者的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 转让股权的用途及对应的价款调整：公司向瑞健健康转让的佰骏医疗股权的用 途进行了调整，拟用于分配的比例由 4.0157%（原为 5.1%，德维特公司对佰骏医疗增资 并受让佰骏医疗股权后稀释至 4.0157%，下同；对应价款 801 万元）调整为 2.4409%（对 应价款 486.6466 万元），相应股权转让款在转让佰骏医疗股权后再进行支付；剩余的 1.5748%股权由公司全资子公司方盛康元通过瑞健健康持有； 其他事项：对于部分尚未通过佰骏医疗股权变现获得收益的股权持有人（对应 佰骏医疗 0.8152%股权），公司同意以扣除依法应当承担的政府税费后的净收益为限支 付转让款，涉及金额最高不超过 170 万元； 风险提示：因目前尚无法准确预计剩余佰骏医疗股权何时进行转让，故收回转让款 时间存 ...